Grant: Strategic Projects - Group
University of Toronto
$179,704.00
Additive manufacturing of organs-on-a-chip using biodegradable elastomeric polymers
EF 2018-19
Résumé
Organ-on-a-chip engineering could revolutionize new compound screening and biomarker discovery. However, current platforms only reproduce a very limited set of organs and lack many critical organ functions such as vasculature, which greatly limits their potential. Recently, we developed AngioChip technology that enabled us to marry two seemingly opposing criteria: permeability and mechanical stability of the vasculature, in a single microfabricated polymer based scaffold for organ-on-a-chip engineering. However, the assembly of the polymer structures necessitated multiple photolithography steps, and manual, layer-by-layer assembly. Despite the great potential of this approach, scaling is not possible using current microfabrication methods. Here, we propose to develop a novel additive manufacturing technology based on 3D printing to directly, automatically and rapidly print polymer scaffolds, with controlled nm-um porosity and with an embedded vasculature ready for 3D organ self-assembly. There are currently no standardized organ-on-a-chip manufacturing technologies, and additive manufacturing is the most promising technology for this unmet need. We will develop new elastomeric polymers to serve as inks and a stereolitography approach for their 3D printing into organ-scaffolds with enclosed lumens. We will design inert cultivation platforms with the dimensions of standard well plates that will each be fitted with a 3D biodegradable mini-organ scaffold ready for cell seeding and pump-free perfusion. Heart and liver tissue will be grown based on human cells, since they are often affected by drug toxicities and novel biomarkers for their functions are critically needed. We will incorporate conductive polymers into the heart-on-a-chip for actuation and field potential sensing. Our supporting organizations will be able to capitalize on this collaboration by using organs-on-a-chip for development of new analytics (Photon), identification of new liver-failure biomarkers (Nucro-technics) and heart-failure biomarkers (TARA Biosystems) as well as relying on organs-on-a-chip for their in-house drug testing projects (Nucro-technics and TARA). Together, they are supporting the project with over $190,000 of in-kind contributions.*
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
506689-2017
Name nom
Radisic, Milica
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
179704
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1586
Committee name en
Strategic Projects - Advanced Manufacturing
Committee name fr
Projets stratégiques - Fabrication de pointe
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
2
Nb partie
2
Application title
Additive manufacturing of organs-on-a-chip using biodegradable elastomeric polymers
Keyword
NSERC
Application summary
Organ-on-a-chip engineering could revolutionize new compound screening and biomarker discovery. However, current platforms only reproduce a very limited set of organs and lack many critical organ functions such as vasculature, which greatly limits their potential. Recently, we developed AngioChip technology that enabled us to marry two seemingly opposing criteria: permeability and mechanical stability of the vasculature, in a single microfabricated polymer based scaffold for organ-on-a-chip engineering. However, the assembly of the polymer structures necessitated multiple photolithography steps, and manual, layer-by-layer assembly. Despite the great potential of this approach, scaling is not possible using current microfabrication methods. Here, we propose to develop a novel additive manufacturing technology based on 3D printing to directly, automatically and rapidly print polymer scaffolds, with controlled nm-um porosity and with an embedded vasculature ready for 3D organ self-assembly. There are currently no standardized organ-on-a-chip manufacturing technologies, and additive manufacturing is the most promising technology for this unmet need. We will develop new elastomeric polymers to serve as inks and a stereolitography approach for their 3D printing into organ-scaffolds with enclosed lumens. We will design inert cultivation platforms with the dimensions of standard well plates that will each be fitted with a 3D biodegradable mini-organ scaffold ready for cell seeding and pump-free perfusion. Heart and liver tissue will be grown based on human cells, since they are often affected by drug toxicities and novel biomarkers for their functions are critically needed. We will incorporate conductive polymers into the heart-on-a-chip for actuation and field potential sensing. Our supporting organizations will be able to capitalize on this collaboration by using organs-on-a-chip for development of new analytics (Photon), identification of new liver-failure biomarkers (Nucro-technics) and heart-failure biomarkers (TARA Biosystems) as well as relying on organs-on-a-chip for their in-house drug testing projects (Nucro-technics and TARA). Together, they are supporting the project with over $190,000 of in-kind contributions.*